Journal: Device

Article Title: SmartSleeve: A sutureless, soft robotic epicardial device that enables switchable on-off drug delivery in response to epicardial ECG sensing

doi: 10.1016/j.device.2024.100419

Figure Lengend Snippet: Figure 1. Overview of the SmartSleeve device and vision for controlled epicardial drug delivery (A) SmartSleeve is a sutureless sensor-enabled soft robotic epicardial drug-delivery device. It is capable of conformal adhesion to the epicardial surface, epicardial ECG sensing, and on-demand epicardial drug delivery in response to the sensed ECG signal. In the future, SmartSleeve could be used to monitor ECG

Article Snippet: To implement ECG-informed on-demand drug delivery in our system, we monitored live heart rate via LabChart software using the ECG analysis add-on package (AD Instruments).

Techniques:

Journal: Device

Article Title: SmartSleeve: A sutureless, soft robotic epicardial device that enables switchable on-off drug delivery in response to epicardial ECG sensing

doi: 10.1016/j.device.2024.100419

Figure Lengend Snippet: Figure 5. Epicardial ECG sensing in small and large animal models (A) Design schematic (i) and realization (ii) of a rodent-sized soft robotic drug-delivery device that can be adhered to the epicardial surface and sense ECG signal. (iii and iv) Representative epicardial and surface ECG signals over the same cardiac cycles. (v) Comparison of RR interval measured from the epicardial and

Article Snippet: To implement ECG-informed on-demand drug delivery in our system, we monitored live heart rate via LabChart software using the ECG analysis add-on package (AD Instruments).

Techniques: Comparison

Journal: Device

Article Title: SmartSleeve: A sutureless, soft robotic epicardial device that enables switchable on-off drug delivery in response to epicardial ECG sensing

doi: 10.1016/j.device.2024.100419

Figure Lengend Snippet: Figure 6. Controlled epicardial drug delivery from an adhesive sensing soft robotic device (A) Amiodarone delivery in a rodent model. (i) Expected physiological changes following amiodarone delivery. (ii) Time for RR interval to increase by 5% following administration of the same dose of amiodarone via device actuation (epicardial delivery; n = 7) vs. i.v. infusion (systemic delivery; n = 3). (iii) Relative change in RR interval following device-enabled epicardial amiodarone delivery with representative epicardial ECG signals used to calculate RR interval before and after device actuation. (iv) Relative change in RR interval following i.v. infusion of amiodarone with representative surface ECG signals used to calculate RR interval before and after infusion. (B) Epinephrine delivery in a porcine model. (i) Expected physiological changes following epinephrine delivery. (ii) Time for RR interval to decrease by 5% following device-enabled epicardial delivery of two different doses of epinephrine (dose 1 = 43 dose 2). (iii) Relative change in RR interval following device-enabled epicardial delivery of epinephrine dose 1 with representative epicardial ECG signals used to calculate RR interval before and after device actuation. (iv) Relative change in RR interval following device-enabled epicardial delivery of epinephrine dose 2 with representative epicardial ECG signals used to calculate RR interval before and after device actuation.

Article Snippet: To implement ECG-informed on-demand drug delivery in our system, we monitored live heart rate via LabChart software using the ECG analysis add-on package (AD Instruments).

Techniques: Adhesive

Journal: Device

Article Title: SmartSleeve: A sutureless, soft robotic epicardial device that enables switchable on-off drug delivery in response to epicardial ECG sensing

doi: 10.1016/j.device.2024.100419

Figure Lengend Snippet: Figure 7. Controlled epicardial drug delivery in response to epicardial ECG sensing via SmartSleeve (A) Epicardial amiodarone delivery in response to real-time epicardial ECG sensing in a rodent model. Device-enabled epicardial amiodarone delivery following sensing of a pre-determined trigger signal (25% decrease in RR interval from baseline). Intravenous administration of glycopyrrolate (expected to increase heart

Article Snippet: To implement ECG-informed on-demand drug delivery in our system, we monitored live heart rate via LabChart software using the ECG analysis add-on package (AD Instruments).

Techniques:

Journal: Journal of Arrhythmia

Article Title: Automated Assessment to Predict Lethal Arrhythmias in Brugada Syndrome: Significance of R' in Lead III

doi: 10.1002/joa3.70166

Figure Lengend Snippet: Representative electrocardiograms (ECGs) with and without events. During the follow‐up period, ventricular fibrillation/sudden cardiac arrest is observed in patients 1–4 but not in patients 5–8. R' in lead III is observed in patients 1–4. The values in the bottom row in patients 1–4 represent the duration of the R' wave in lead III, calculated using automated analysis. Red arrows indicate R' in lead III. Asterisks indicate type 1 ECG. Patients 1, 2, and 4 do not meet the definition of fragmented QRS in the inferior leads (≥ 3 spikes in ≥ 2 leads) as defined by Morita et al. .

Article Snippet: The numerical values of the various parameters (RR, PQ, QRS, QT, and Tpeak‐end [Tpe] intervals; amplitude and duration of R, S, R', and J waves in all leads; maximum QT interval; and maximum Tpe interval among all leads and nine right precordial leads) on ECG were analyzed using the automatic ECG analysis software (Fukuda Denshi TG02‐06).

Techniques:

Journal: JACC: Basic to Translational Science

Article Title: Decreased FAM13B Expression Increases Atrial Fibrillation Susceptibility by Regulating Sodium Current and Calcium Handling

doi: 10.1016/j.jacbts.2023.05.009

Figure Lengend Snippet: Heart Structure Function and Basal ECG of WT and Fam13b KO mice (A) Ejection fraction (left) and left ventricular mass (right) in male wild-type (WT) (n = 5) and knockout (KO) (n = 8) mice (means shown, Student’s t -test). (B) Heart (left) and heart weight normalized to tibial length (right side) in male (top, 14 WT and 14 KO) and female (bottom, 7 WT and 4 KO) mice (means shown, Student’s t -test). (C) Gross appearance of representative perfused and fixed hearts ex vivo (Males, left; females, right, WT, top; KO, bottom). (D) Four-chamber fixed section stained with hematoxylin-eosin (H&E) and Masson’s Trichrome. (E) Basal electrocardiogram (ECG) readings in male (left, 17 WT and 19 KO) and female (right, 11 WT and 9 KO) WT (black symbols) and KO (red symbols) mice, with each symbol representing a biological replicate. Data were analyzed by Mann-Whitney tests, with median values shown (∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001). P = duration of P-wave; PR = duration of PR interval; QRS = duration of QRS peak; QT = duration of QT interval; QTc = duration of QT interval corrected for a standard heart cycle; RR = duration of heart cycle via RR interval.

Article Snippet: LabScribe ECG Analysis software (iWorx RA834) was used for the intracardiac recordings and assessment.

Techniques: Knock-Out, Ex Vivo, Staining, MANN-WHITNEY

Journal: JACC: Basic to Translational Science

Article Title: Decreased FAM13B Expression Increases Atrial Fibrillation Susceptibility by Regulating Sodium Current and Calcium Handling

doi: 10.1016/j.jacbts.2023.05.009

Figure Lengend Snippet: Intracardiac Pacing-Induced Arrhythmia (A) Representative surface electrocardiogram (ECG) and atrial intracardiac electrogram from a female Fam13b knockout (KO) mouse showing burst pacing followed by an occurrence of atrial fibrillation (AF) with RR variability and P-wave disruption (SR, sinus rhythm phase with normal P waves and double-headed blue arrows showing the regular RR interval; Stimulus, showing the programmed electrical stimulation; AF, the atrial fibrillation phase with rapid and chaotic atrial activation with lack of regular P waves, the double-headed red arrows showing RR interval variability). AF events stopped spontaneously followed by normal SR. (B) Poincare plot showing representative RR variability in a single female Fam13b KO before (black symbols) and after pacing-induced AF (red symbols), with the median RR variability 18 times larger in AF ( P < 0.001, Mann-Whitney test). (C, D) Representative surface ECGs and intracardiac recordings from 2 male Fam13b KO mice showing instances of ventricular arrhythmia due to premature ventricular contractions (PVC).

Article Snippet: LabScribe ECG Analysis software (iWorx RA834) was used for the intracardiac recordings and assessment.

Techniques: Knock-Out, Disruption, Activation Assay, MANN-WHITNEY

Journal: Journal of the American Association for Laboratory Animal Science : JAALAS

Article Title: Use of Ketamine or Xylazine to Provide Balanced Anesthesia with Isoflurane in C57BL/6J Mice

doi: 10.30802/AALAS-JAALAS-21-000125

Figure Lengend Snippet: (A) ECG recording from a control mouse showing a premature ventricular contraction. Note the changes in the conformation of the 4th contraction compared with the other, normal contractions. (B) ECG recording showing atrial premature contractions. Note the decreased interval between the 4th and 5th complexes. Mice in all 3 groups had atrial premature contractions noted on ECG.

Article Snippet: In addition, in experiment 4, a continuous electrocardiogram monitoring system (ECGenie and eMouse 11 Analysis Software, Mouse Specifics) was used to monitor for cardiac arrhythmias and HR variability.

Techniques: Control

Journal: Experimental Animals

Article Title: Usefulness of simultaneous and sequential monitoring of glucose level and electrocardiogram in monkeys treated with gatifloxacin under conscious and nonrestricted conditions

doi: 10.1538/expanim.17-0136

Figure Lengend Snippet: Effect of gatifloxacin on electrocardiogram in monkeys. Animals were treated with a single oral dose of the vehicle (0 mg/kg) or gatifloxacin at 10, 30, 60 or 100 mg/kg. Data are presented as mean ± SE (n=4) for each group. * P <0.05, ** P <0.01: significantly different from the vehicle control group.

Article Snippet: The ECG components (PR interval, QRS width and QT interval) were analyzed with an ECG analysis software (HS1000VL; Fukuda M-E Kogyo Co., Ltd.) based on the stable ECG waveform obtained around 0.5 h before dosing and at 1, 2, 4, 6, 12 and 24 h after dosing.

Techniques: Control